Home > Insider Trading > Filing (0001123292-14-000781)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1437786	Immune Design Corp.	IMDZ	Pharmaceutical Preparations (2834)	262007174

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1182464	V David Goeddel	1700 Owens Street, Suite 500 San Francisco CA 94158	No	No	Yes	No
1347769	P L Group Column	1700 Owens Street, Suite 500 San Francisco CA 94158	No	No	Yes	No
1614627	Column Group Gp, Lp	1700 Owens Street, Suite 500 San Francisco CA 94158	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-07-29	733,943	$0.00	733,943	No	4	C	Direct
Common Stock	Acquisiton	2014-07-29	744,580	$0.00	1,478,523	No	4	C	Direct
Common Stock	Acquisiton	2014-07-29	856,269	$0.00	2,334,792	No	4	C	Direct
Common Stock	Acquisiton	2014-07-29	428,134	$0.00	2,762,926	No	4	C	Direct
Common Stock	Acquisiton	2014-07-29	399,016	$12.00	3,161,942	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2014-07-29	733,943	$0.00	733,943	$0.00
Common Stock	Series B Preferred Stock	Disposition	2014-07-29	744,580	$0.00	744,580	$0.00
Common Stock	Series C Preferred Stock	Disposition	2014-07-29	856,269	$0.00	856,269	$0.00
Series C Preferred Stock	Series C Preferred Stock Warrant (right to buy)	Disposition	2014-07-29	428,134	$0.00	428,134	$8.18
Common Stock	Series C Preferred Stock	Acquisiton	2014-07-29	428,134	$0.00	428,134	$0.00
Common Stock	Series C Preferred Stock	Disposition	2014-07-29	428,134	$0.00	428,134	$0.00

Remaning Holdings	Exercise Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		No	4	C	Direct
0		No	4	C	Direct
0		No	4	C	Direct
0	2013-10-16	No	4	X	Direct
428,134		No	4	X	Direct
0		No	4	C	Direct

Footnotes

Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date.
The securities are directly held by The Column Group, LP and indirectly held by The Column Group GP, LP ("TCG GP") the general partner of The Column Group, LP. TCG GP has voting and dispositive power with respect to these shares. The individual managing partners of TCG GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of their pecuniary interest therein.
The warrants were set to expire on the earlier of: (a) October 15, 2015, (b) the latter of (i) 30 days after delivery to the warrant holder of the interim study report of a specified clinical trial by the Issuer or (ii) 30 days after notice to the warrant holder of the commencement of patient recruitment for specified studies or trials by the Issuer, (c) a liquidation event of the Issuer or (d) the closing of the Issuer's initial public offering.